Lithium

A novel treatment for Alzheimer's disease?

Jin Zhong, Wei Hua Lee

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Lithium is an alkali metal. First described as a mood stabilizer in 1949, it remains an efficacious treatment for bipolar disorders. Recent emerging evidence of its neuroprotective and neurogenic effects alludes to lithium's potential therapeutic use in stroke and neurodegenerative diseases. One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower τ and β-amyloid levels in cerebrospinal fluid in Alzheimer's patients. This review summarizes the supporting evidence and safety profiles of lithium's use in the treatment of neurological diseases, especially Alzheimer's disease.

Original languageEnglish
Pages (from-to)375-383
Number of pages9
JournalExpert Opinion on Drug Safety
Volume6
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

Lithium
Alzheimer Disease
Alkali Metals
Aptitude
Neuroprotective Agents
Therapeutic Uses
Therapeutics
Bipolar Disorder
Amyloid
Neurodegenerative Diseases
Cerebrospinal Fluid
Stroke
Clinical Trials
Safety

Keywords

  • Alzheimer's disease
  • Glycogen synthase kinase
  • Lithium
  • Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Lithium : A novel treatment for Alzheimer's disease? / Zhong, Jin; Lee, Wei Hua.

In: Expert Opinion on Drug Safety, Vol. 6, No. 4, 07.2007, p. 375-383.

Research output: Contribution to journalArticle

Zhong, Jin ; Lee, Wei Hua. / Lithium : A novel treatment for Alzheimer's disease?. In: Expert Opinion on Drug Safety. 2007 ; Vol. 6, No. 4. pp. 375-383.
@article{1999276d9d3946b18c908717b329f1e5,
title = "Lithium: A novel treatment for Alzheimer's disease?",
abstract = "Lithium is an alkali metal. First described as a mood stabilizer in 1949, it remains an efficacious treatment for bipolar disorders. Recent emerging evidence of its neuroprotective and neurogenic effects alludes to lithium's potential therapeutic use in stroke and neurodegenerative diseases. One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower τ and β-amyloid levels in cerebrospinal fluid in Alzheimer's patients. This review summarizes the supporting evidence and safety profiles of lithium's use in the treatment of neurological diseases, especially Alzheimer's disease.",
keywords = "Alzheimer's disease, Glycogen synthase kinase, Lithium, Safety",
author = "Jin Zhong and Lee, {Wei Hua}",
year = "2007",
month = "7",
doi = "10.1517/14740338.6.4.375",
language = "English",
volume = "6",
pages = "375--383",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Lithium

T2 - A novel treatment for Alzheimer's disease?

AU - Zhong, Jin

AU - Lee, Wei Hua

PY - 2007/7

Y1 - 2007/7

N2 - Lithium is an alkali metal. First described as a mood stabilizer in 1949, it remains an efficacious treatment for bipolar disorders. Recent emerging evidence of its neuroprotective and neurogenic effects alludes to lithium's potential therapeutic use in stroke and neurodegenerative diseases. One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower τ and β-amyloid levels in cerebrospinal fluid in Alzheimer's patients. This review summarizes the supporting evidence and safety profiles of lithium's use in the treatment of neurological diseases, especially Alzheimer's disease.

AB - Lithium is an alkali metal. First described as a mood stabilizer in 1949, it remains an efficacious treatment for bipolar disorders. Recent emerging evidence of its neuroprotective and neurogenic effects alludes to lithium's potential therapeutic use in stroke and neurodegenerative diseases. One intriguing clinical application is in the treatment of Alzheimer's disease. Ongoing clinical trials are evaluating lithium's abilities to lower τ and β-amyloid levels in cerebrospinal fluid in Alzheimer's patients. This review summarizes the supporting evidence and safety profiles of lithium's use in the treatment of neurological diseases, especially Alzheimer's disease.

KW - Alzheimer's disease

KW - Glycogen synthase kinase

KW - Lithium

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=34548478820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548478820&partnerID=8YFLogxK

U2 - 10.1517/14740338.6.4.375

DO - 10.1517/14740338.6.4.375

M3 - Article

VL - 6

SP - 375

EP - 383

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -